Tizona Therapeutics is a US immunotherapy company developing a pipeline of novel antibody therapeutics with potential in a broad range of cancers and autoimmune diseases. Tizona’s lead candidate is expected to start clinical trials in 2019 for cancer.

LocationSouth San Francisco, California
CEOScott Clarke
Partner Shelley Chu
Websitewww.tizonatx.com